| Title | Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies |
|---|---|
| Author | Jung-ah Choi and Jae-Ouk Kim* |
| Address | Science Unit, International Vaccine Institute, Seoul 08826, Republic of Korea |
| Bibliography | Journal of Microbiology, 60(3),238-246, 2022, |
| DOI | 10.1007/s12275-022-1547-8 |
| Key Words | Middle East Respiratory Syndrome coronavirus (MERS-CoV), vaccine, platform technologies |
| Abstract | Middle East Respiratory Syndrome coronavirus (MERS-CoV), a contagious zoonotic virus, causes severe respiratory infection with a case fatality rate of approximately 35% in humans. Intermittent sporadic cases in communities and healthcare facility outbreaks have continued to occur since its first identification in 2012. The World Health Organization has declared MERS-CoV a priority pathogen for worldwide research and vaccine development due to its epidemic potential and the insufficient countermeasures available. The Coalition for Epidemic Preparedness Innovations is supporting vaccine development against emerging diseases, including MERS-CoV, based on platform technologies using DNA, mRNA, viral vector, and protein subunit vaccines. In this paper, we review the usefulness and structure of a spike glycoprotein as a MERSCoV vaccine candidate molecule, and provide an update on the status of MERS-CoV vaccine development. Vaccine candidates based on both DNA and viral vectors coding MERSCoV spike gene have completed early phase clinical trials. A harmonized approach is required to assess the immunogenicity of various candidate vaccine platforms. Platform technologies accelerated COVID-19 vaccine development and can also be applied to developing vaccines against other emerging viral diseases. |